The BioCentury Show

Tune in to BioCentury’s in-depth conversations with global leaders who are advancing the future of medicine. Join our Senior Editors in face-to-face discussions with scientific KOLs, top executives, VCs, and key policymakers, dissecting the most urgent public health issues. The BioCentury Show is THE only place where BioCentury’s experts join top innovators and global influencers to show how science is being turned into medicine. Don't miss this event, every two weeks, now available as a video webcast or audio podcast .

The BioCentury Show is a science podcast hosted by BioCentury, with 71 episodes on record and a Required Pod Score of 80.

BioCentury hosts The BioCentury Show, a science show with 71 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  Episode #118

  Ep. 118 - Regeneron's Gonçalo Abecasis on turning genetic data into drug targets

  Sep 3, 202632 minS5

  On This Edition of The BioCentury Show , Gonçalo Abecasis, SVP and Chief Genomics and Data Sciences Officer at the Regeneron Genetics Center, joins BioCentury’s Tierney Baum to discuss genetics as a scalable drug discovery platform and the practical use of AI in genomics. View full story: https://www.biocentury.com/article/660697 #Genomics #DrugDiscovery #AI #GeneticMedicines #ClinicalTrials 0:00 - Introduction 1:14 - Regeneron Genetics Center 10:29 - Acting on Genetic Signals 16:57 - Getting to Drug Development 21:51 - Best AI Use Cases

  ListenShow Notes
• 

  Episode #117

  Ep. 117 - C-Path's Klaus Romero on moving genetic medicines beyond one patient

  Aug 20, 202630 minS5

  The Critical Path Institute’s One to Millions Initiative is using individualized rare disease therapies as the starting point for a development framework that could eventually extend across all genetically defined diseases. The initiative seeks to bring form to FDA’s Plausible Mechanism Framework by standardizing how evidence and methods can be reused across therapies and patients. In conversation with Biopharma Analyst Dr. Tierney Baum on The BioCentury Show , C-Path CEO and CSO Klaus Romero discusses how the principal bottleneck is no longer the ability to design therapies for individual patients but rather the absence of a standardized regulatory and development system that can translate one success into many. C-Path plans to bring companies, academics, patient groups, and regulators together to share data and address recurring development bottlenecks. View full story: https://www.biocentury.com/article/660583 #GeneticMedicines #RareDisease #DrugDevelopment #RegulatoryScience #ClinicalTrials 00:00 - Introduction 01:44 - Current Framework 07:01 - Process-based Regulation 13:57 - Overcoming Bottlenecks 20:28 - Use of AI 25:25 - Beyond Rare Diseases

  ListenShow Notes
• 

  Episode #116

  Ep. 116 - Ovid's Jeremy Levin on biotech in the balance

  Aug 6, 202633 minS5

  Throughout his career, which has included serving as president and CEO of Teva, chair of BIO, and a leader or senior executive of large and small biopharma companies, Jeremy Levin has challenged the industry to live up to its ideals. In an interview with BioCentury Washington Editor Steve Usdin, Levin discussed why he believes industry leaders should speak out, and why many remain silent, about critical issues. He described concerns about the strength of the pillars that support the U.S. biotech industry, and why he is optimistic about the future of biotech. View full story: https://www.biocentury.com/article/660408 #Biotech #DrugPricing #BiopharmaPolicy #ChinaBiotech #Innovation 00:00 - Introduction 03:24 - Biotech Under Threat 10:38 - CEO Compensation 15:39 - Competing with China 22:08 - U.S. Policy Prescriptions 30:00 - Looking Ahead

  ListenShow Notes
• 

  Episode #115

  Ep. 115 - Initiate's Owens on what it takes to be AI-native

  Jul 22, 202640 minS5

  As AI becomes increasingly commoditized, Initiate Ventures' Jessica Owens argues healthcare and life sciences companies need to use it to solve historically intractable problems, not just streamline workflows. On The BioCentury Show , Owens breaks down how she evaluates founders, when Initiate chooses to fund versus co-found a company, and why she believes proprietary data now matters more than any proprietary model. Owens also discusses gaps in evidence generation for diagnostics, and closes with a look at MASH, arguing that better non-invasive fibrosis staging will become increasingly critical as more GLP-1 combination therapies reach patients. View full story: https://www.biocentury.com/article/660203 #AI #VentureCapital #Diagnostics #HealthTech #DrugDevelopment 00:00 - Introduction 01:15 - Initiate Ventures' Thesis 07:04 - What Makes Founders Fundable 17:36 - Defining AI Native Healthcare 23:20 - Diagnostics & Evidence Generation 36:44 - Non-Invasive Fibrosis Testing

  ListenShow Notes
• 

  Episode #114

  Ep. 114 - Roivant’s Matt Gline on commercial launches and the future of the vant model

  Jul 9, 202642 minS5

  Roivant CEO Matt Gline calls the company’s move beyond spinning out subsidiary “vants” to concentrating on late-stage programs and commercial launches less a pivot than an evolution toward an original goal, which could soon be realized with the approval and launch of brepocitinib this year. In conversation with Lindsay Martin on The BioCentury Show , Gline discussed how Roivant’s initial hub-and-spoke approach has provided the foundation needed for the company to develop and commercialize its portfolio now, including lead program JAK-1/TYK2 inhibitor brepocitinib. Gline also discussed how he views AI at Roivant and more broadly in biopharma R&D, the science behind Roivant’s next most advanced program, Phase III anti-FcRN mAb imeroprubart and the lessons he’s taking from a “graduating class” of biotechs that have launched programs, like Alnylam and Argenx S.E. View full story: https://www.biocentury.com/article/660059 #DrugDevelopment #BiotechInnovation #Commercialization #ArtificialIntelligence #BiopharmaStrategy 00:00 - Introduction 00:42 - Roivant’s Evolution 09:19 - AI in R&D 17:48 - Lead Asset Brepocitinib 28:23 - Anti-FcRN mAb Imeroprubart 32:23 - China 37:55 - What’s Next for Roivant

  ListenShow Notes

Recent guests on The BioCentury Show. Study who booked and why before you pitch.

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.